Cellular immunotherapies represent long-term opportunity

5 May 2016
2019_biotech_test_vial_discovery_big

While cellular immunotherapies, which encompass dendritic cell therapy and chimeric antigen receptor T-cell (CAR-T) therapy, are expected to show promising results in combination treatments in the next few years, they are unlikely to make a significant impact on the immuno-oncology market in the short term.

According to research and consulting firm GlobalData’s latest report, recent advancements in the field of adoptive T-cell therapy have created much excitement surrounding CAR-T therapy as a potential cure for a variety of cancers. Indeed, the treatment hit the headlines in February 2016 after a preliminary clinical trial found that six out of the seven patients treated with CAR-T therapy were in complete remission.

Dan Roberts, GlobalData’s senior analyst covering oncology and hematology, says: “Although the immuno-oncology space will be dominated by immune checkpoint inhibitors, which GlobalData forecasts to achieve sales of $24 billion by 2024, cellular immunotherapies and cancer vaccines will continue to be pursued, despite past failures.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology